Table 3.
Individual standardized AGREE domain scores (in %) for the guidelines studied.
| Scope and purpose | Stakeholder involvement | Rigor of development | Clarity and presentation | Applicability | Editorial independence | |
|---|---|---|---|---|---|---|
| Dyslipidemia[18] | 83.3 | 33.3 | 81.0 | 100 | 44.4 | 100 |
| Chronic impaired renal function[19] | 100 | 66.6 | 78.6 | 100 | 72.2 | 100 |
| Heart failure[20] | 77.8 | 62.5 | 71.4 | 87.5 | 38.8 | 100 |
| Anticoagulant therapy[21] | 100 | 62.5 | 42.9 | 100 | 75 | 62.3 |
| Obesity[22] | 100 | 62.5 | 100 | 91.7 | 83.3 | 91.7 |
| Atrial fibrillation[23] | 88.9 | 25.0 | 64.3 | 71.0 | 22.2 | 25.0 |
| Peripheral arterial disease[24] | 94.4 | 25.3 | 78.6 | 100 | 33.3 | 50.0 |
| COPD[25] | 94.4 | 75.0 | 78.6 | 100 | 66.7 | 66.7 |
| Osteoporosis[26] | 100 | 25.0 | 71.4 | 75.0 | 33.3 | 33.3 |
| Rheumatoid arthritis | 88.9 | 25.0 | 47.6 | 58.3 | 22.2 | 41.7 |
| Diabetes mellitus[28] | 88.9 | 83.3 | 100 | 100 | 88.9 | 100 |
| Asthma[29] | 88.9 | 66.7 | 85.7 | 91.7 | 16.7 | 66.7 |
| Dementia[30] | 100 | 79.2 | 90.5 | 58.3 | 11.1 | 100 |
| Glaucoma[31] | 100 | 66.7 | 100 | 100 | 77.8 | 100 |
| Anxiety[32] | 91.7 | 68.3 | 85.6 | 100 | 33.3 | 66.7 |
| Hypertension[33] | 91.7 | 55.0 | 97.1 | 95.0 | 48.9 | 86.7 |